JPWO2013065651A1 - Method for producing protein fiber - Google Patents

Method for producing protein fiber Download PDF

Info

Publication number
JPWO2013065651A1
JPWO2013065651A1 JP2012077922A JP2013541771A JPWO2013065651A1 JP WO2013065651 A1 JPWO2013065651 A1 JP WO2013065651A1 JP 2012077922 A JP2012077922 A JP 2012077922A JP 2013541771 A JP2013541771 A JP 2013541771A JP WO2013065651 A1 JPWO2013065651 A1 JP WO2013065651A1
Authority
JP
Japan
Prior art keywords
protein
solvent
solution
mass
silk fibroin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012077922A
Other languages
Japanese (ja)
Other versions
JP5584932B2 (en
Inventor
潤一 菅原
潤一 菅原
和秀 関山
和秀 関山
涼太 佐藤
涼太 佐藤
香里 関山
香里 関山
瑞季 石川
瑞季 石川
真也 村田
真也 村田
Original Assignee
スパイバー株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2011241487 priority Critical
Priority to JP2011241487 priority
Application filed by スパイバー株式会社 filed Critical スパイバー株式会社
Priority to JP2013541771A priority patent/JP5584932B2/en
Priority to PCT/JP2012/077922 priority patent/WO2013065651A1/en
Application granted granted Critical
Publication of JP5584932B2 publication Critical patent/JP5584932B2/en
Publication of JPWO2013065651A1 publication Critical patent/JPWO2013065651A1/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • DTEXTILES; PAPER
    • D01NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01DMECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
    • D01D5/00Formation of filaments, threads, or the like
    • D01D5/06Wet spinning methods
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43586Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
    • DTEXTILES; PAPER
    • D01NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01FCHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F4/00Monocomponent artificial filaments or the like of proteins; Manufacture thereof
    • D01F4/02Monocomponent artificial filaments or the like of proteins; Manufacture thereof from fibroin

Abstract

The protein solution of the present invention is a protein solution in which a protein component containing silk fibroin is dissolved in a solvent, and the solvent includes dimethyl sulfoxide, N, N-dimethylformamide, N, N-dimethylacetamide and N-methyl- It contains at least one polar solvent selected from 2-pyrrolidone and an inorganic salt. The fiber production method of the present invention uses the protein solution as a dope liquid, extrudes it from a die into a coagulating liquid in a solvent removal tank, desorbs the solvent from the dope liquid and forms fibers to form an undrawn yarn, Obtain protein fiber. This provides a protein solution containing silk fibroin with high solubility of the medium, high boiling point, high temperature dissolution, high safety, and low cost of the solvent itself, and a method for producing protein fiber using the same. .

Description

  The present invention relates to a protein solution containing silk fibroin and a method for producing a protein fiber using the same.

  Artificial silk fiber using silk fibroin is conventionally known as regenerated silk fiber. Patent Document 1 describes the use of hexafluoroacetone (HFAc) hydrate as a solvent, Patent Document 2 describes the use of hexafluoroisopropanol (HFIP), and Patent Document 3 discloses water, The use of formic acid, hexafluoroacetone (HFac) hydrate, hexafluoroisopropanol (HFIP) is described.

JP 2004-068161 A JP-T-2006-504450 JP 2010-270426 A

  However, conventional solvents used to dissolve silk fibroin are expensive such as hexafluoroisopropanol (HFIP) and hexafluoroacetone (HFAc), difficult to dissolve like water and formic acid, HFIP, etc. Then there was a safety problem.

  In order to solve the above-mentioned conventional problems, the present invention provides a protein solution containing silk fibroin having a high solubility in a medium, a high boiling point and capable of high-temperature dissolution, high safety, and low cost of the solvent itself. A method for producing the protein fiber used is provided.

  The protein solution of the present invention is a protein solution in which a protein component containing silk fibroin is dissolved in a solvent, and the solvent includes dimethyl sulfoxide, N, N-dimethylformamide, N, N-dimethylacetamide and N-methyl- It contains at least one polar solvent selected from 2-pyrrolidone and an inorganic salt.

  The method for producing a protein fiber of the present invention is a method for producing a protein fiber containing silk fibroin using the protein solution as a dope solution, and the dope solution is extruded from a base into a coagulating solution in a desolvation tank, and the dope is produced. The solvent is removed from the liquid and fibers are formed to form undrawn yarns to obtain protein fibers.

  The protein solution of the present invention is a protein solution in which a protein component containing silk fibroin (hereinafter also referred to as “medium”) is dissolved in a solvent, and the solvent is dimethyl sulfoxide (DMSO), N, N-dimethylformamide ( DMF), N, N-dimethylacetamide (DMA) and N-methyl-2-pyrrolidone (NMP) contain at least one polar solvent and inorganic salt, so that the solubility of the medium is high and the boiling point is high. High-temperature dissolution is possible, safety is high, and the cost of the solvent itself can be reduced. If the solubility of the medium is high and it can be dissolved at a high concentration, the production efficiency of fibers and films can be increased. If the boiling point is high and high temperature dissolution is possible, the dope solution adjustment work can be made efficient. If safety is high, production workability can be improved and application development can be expanded. Furthermore, the solution of the present invention has spinnability and is useful for wet spinning, cast film and the like.

FIG. 1 is an explanatory view showing a manufacturing apparatus in one embodiment of the present invention. 2A and 2B are explanatory views showing a production apparatus according to another embodiment of the present invention. FIG. 2A shows a spinning apparatus—first stage stretching apparatus, and FIG. 2B shows a second stage stretching apparatus. FIG. 3 is an explanatory view showing a manufacturing apparatus in still another embodiment of the present invention. 4A and 4B are explanatory views showing a production apparatus according to still another embodiment of the present invention. FIG. 4A shows a spinning apparatus and FIG. 4B shows a drawing apparatus. FIG. 5 is a stress-displacement (strain) curve of a single fiber obtained in Example 2 of the present invention. FIG. 6 is a stress-displacement (strain) curve of a single fiber obtained in Example 3 of the present invention. FIG. 7 is a stress-displacement (strain) curve of a single fiber obtained in Example 4 of the present invention. FIG. 8 is a stress-displacement (strain) curve of a single fiber obtained in Example 5 of the present invention. FIG. 9 is a stress-displacement (strain) curve of a single fiber obtained in Example 6 of the present invention. FIG. 10 is a stress-displacement (strain) curve of the single fiber obtained in Example 7 of the present invention.

1. Solvent (1) Selection of polar solvent As specifically described in the Examples, the present inventors have examined what kind of solvent is appropriate as a protein solution in which a protein component containing silk fibroin is dissolved in a solvent. did. As will be described in the examples, dissolution experiments were conducted mainly with polar solvents. As a result, an inorganic salt is added to at least one polar solvent selected from dimethyl sulfoxide (DMSO), N, N-dimethylformamide (DMF), N, N-dimethylacetamide (DMA) and N-methyl-2-pyrrolidone (NMP). It has been found that a solvent containing a high solubility selectively enables high-temperature dissolution. When the protein solution is 100% by mass, the concentration (solubility) of the medium is preferably 3% by mass or more, more preferably 5% by mass or more, and further preferably 6% by mass or more. When the protein solution is 100% by mass, the concentration (solubility) of the medium is preferably 45% by mass or less, more preferably 30% by mass or less, and further preferably 25% by mass or less. DMSO has a melting point of 18.4 ° C. and a boiling point of 189 ° C., DMF has a melting point of −61 ° C. and a boiling point of 153 ° C., hexafluoroisopropanol (HFIP) has a boiling point of 59 ° C. The boiling point is much higher than the boiling point -26.5 ° C. In addition, the polar solvent is used as a polymerization solution and spinning solution for acrylic fibers in general industrial fields, and is also used as a polymerization solvent and dilution solvent for polyimide. Therefore, the cost is low and safety is also confirmed. It is a substance.

(2) Dissolution accelerator An inorganic salt is added to the polar solvent as a dissolution accelerator. Examples of inorganic salts include alkali metal halides (eg, LiCl, LiBr, etc.), alkaline earth metal halides (eg, CaCl 2 ), alkaline earth metal nitrates (eg, Ca (NO 3 ) 2 ), thiocyanate (eg, NaSCN etc.). When the solvent is 100% by mass, the proportion of the inorganic salt is preferably in the range of 0.1 to 20% by mass.

(3) Solvent purity and additives The solvent may further contain alcohol and / or water. When the solvent is 100% by mass, the ratio of the polar solvent to the inorganic salt is 20% by mass to 100% by mass, and the remainder may contain alcohol. In the above, the alcohol is preferably a lower alcohol having 1 to 6 carbon atoms. More preferred is methanol, ethanol or 2-propanol.

  When water is included, when the solvent is 100% by mass, the ratio of the polar solvent and the inorganic salt is 10% by mass or more and 100% by mass or less, and the remainder may contain water. You may mix water and alcohol.

2. Protein component The protein component may be 100% by mass of silk fibroin, or a mixture of silk fibroin and other polypeptides. Polypeptides other than silk fibroin are preferably polypeptides derived from spider silk proteins that are excellent in properties such as stress and elongation at break. That is, when the protein component is 100% by mass, the polypeptide derived from silk fibroin: spider silk protein in a mass ratio is preferably 100: 0 to 10:90. If it is the said range, there exists preferable spinnability, both components are favorable affinity without peeling, it becomes a hybrid fiber, and it becomes a protein fiber with a high stress and a moderate elongation at break.

  Silk fibroin may be derived from or similar to natural silk fibroin. Natural or domestic silkworms or used or discarded silk fabrics are used as raw materials to remove sericin covering silk fibroin and other fats. A silk fibroin lyophilized powder obtained by purifying the silk fibroin is preferred.

In the present invention, the polypeptide derived from a spider silk protein is not particularly limited, and for example, a polypeptide derived from a natural spider silk protein can be used. The polypeptide is not particularly limited as long as it is derived from a natural spider silk protein, and a natural spider silk protein or a recombinant spider silk protein, for example, a mutant, analog or derivative of a natural spider silk protein Etc. From the viewpoint of excellent toughness, the polypeptide is preferably a polypeptide derived from a large sputum bookmark thread protein produced in a spider large bottle-like line. Examples of the large sputum bookmark thread protein include large bottle-shaped wire spidroins MaSp1 and MaSp2 derived from Nephila clavipes, and ADF3 and ADF4 derived from two spider spiders (Araneus diadematus). The polypeptide derived from the large sputum bookmark thread protein includes a mutant, analog or derivative of the large sputum bookmark thread protein.

  Examples of the polypeptide derived from the large sputum dragline protein include a polypeptide comprising 2 or more, preferably 5 or more, more preferably 10 or more amino acid sequence units represented by Formula 1: REP1-REP2 (1). Can be mentioned. In addition, in the polypeptide derived from the large sputum dragline protein, the unit of the amino acid sequence represented by Formula 1: REP1-REP2 (1) may be the same or different. From the viewpoint of productivity, the polypeptide derived from the large sputum bookmark thread protein preferably has a molecular weight of 500 kDa or less, more preferably 300 kDa, from the viewpoint of productivity when producing a recombinant protein using a microorganism such as Escherichia coli as a host. Or less, more preferably 200 kDa or less.

  In the above formula 1, REP1 means polyalanine. In the REP1, alanine arranged continuously is preferably 2 residues or more, more preferably 3 residues or more, still more preferably 4 residues or more, particularly preferably 5 residues or more. It is. In the REP1, alanine continuously arranged is preferably 20 residues or less, more preferably 16 residues or less, still more preferably 12 residues or less, and particularly preferably 10 residues. Below the group. In Formula 1, REP2 is an amino acid sequence consisting of 10 to 200 amino acids, and the total number of residues of glycine, serine, glutamine and alanine contained in the amino acid sequence is based on the total number of amino acid residues. It is 40% or more, preferably 60% or more, more preferably 70% or more.

  In a large splint bookmarker, the REP1 corresponds to a crystal region forming a crystal β sheet in the fiber, and the REP2 is an amorphous type that is more flexible in the fiber and largely lacks a regular structure. Corresponds to the area. [REP1-REP2] corresponds to a repetitive region (repetitive sequence) composed of a crystal region and an amorphous region, and is a characteristic sequence of a bookmark thread protein.

  As the polypeptide comprising two or more units of the amino acid sequence represented by Formula 1: REP1-REP2 (1), for example, a polypeptide consisting of the amino acid sequence represented by any one of SEQ ID NOs: 1 to 3 can be used. . The polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1 is an amino acid sequence of ADF3 in which an amino acid sequence (SEQ ID NO: 4) consisting of a start codon, His10 tag and HRV3C protease (Human rhinovirus 3C protease) recognition site is added to the N-terminus ( NCBI accession number: AAC47010, GI: 1263287), and the first to thirteenth repetitive region was increased to about double and the translation was mutated to stop at the 1154th amino acid residue. is there. The polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 2 recognizes a start codon, His10 tag and HRV3C protease (Human rhinovirus 3C protease) at the N-terminus of a partial amino acid sequence of ADF3 (GI: 1263287, NCBI accession number). An amino acid sequence consisting of a site (SEQ ID NO: 4) is added. The polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 3 is an amino acid sequence of ADF3 in which an amino acid sequence (SEQ ID NO: 4) consisting of a start codon, His10 tag and HRV3C protease (Human rhinovirus 3C protease) recognition site is added to the N-terminus ( NCBI accession number: AAC47010, GI: 1263287), and the first to thirteenth repeated regions are increased to be approximately doubled.

  Examples of the polypeptide containing two or more units of the amino acid sequence represented by Formula 1: REP1-REP2 (1) include one or more amino acids in the amino acid sequence represented by any one of SEQ ID NOs: 1 to 3, for example. Can be used which has an amino acid sequence substituted, deleted, inserted and / or added and having a repetitive region consisting of a crystalline region and an amorphous region. In the present invention, “one or more” means, for example, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, Or one or several. In the present invention, “one or several” means 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, Means two or one.

  The polypeptide can be produced using a host transformed with an expression vector containing a gene encoding the polypeptide. The method for producing the gene is not particularly limited, and a gene encoding a natural spider silk protein is amplified and cloned from a spider-derived cell by polymerase chain reaction (PCR) or the like, or chemically synthesized. The method for chemically synthesizing the gene is not particularly limited. For example, based on the amino acid sequence information of the natural spider silk protein obtained from the NCBI web database, etc., AKTA oligopilot plus 10/100 (GE Healthcare Japan Co., Ltd.) Oligonucleotides automatically synthesized by a company) can be synthesized by ligation by PCR or the like. At this time, in order to facilitate the purification and confirmation of the protein, a gene encoding a protein consisting of an amino acid sequence in which an amino acid sequence consisting of a start codon and a His10 tag is added to the N terminus of the above amino acid sequence may be synthesized. .

  As the expression vector, a plasmid, phage, virus or the like capable of expressing a protein from a DNA sequence can be used. The plasmid type expression vector is not particularly limited as long as the gene of interest can be expressed in the host cell and can be amplified by itself. For example, when Escherichia coli Rosetta (DE3) is used as a host, a pET22b (+) plasmid vector, a pCold plasmid vector, or the like can be used. Among these, it is preferable to use a pET22b (+) plasmid vector from the viewpoint of protein productivity. As the host, for example, animal cells, plant cells, microorganisms and the like can be used.

  The polypeptide derived from the spider silk protein used in the present invention is preferably a polypeptide derived from ADF3, which is one of the two main drag proteins of Araneus diadematus. An advantage of this polypeptide is that it has basically high elongation and toughness and is easy to synthesize.

3. Protein Solution A solution containing protein can be used as a dope solution. The dope solution is useful for wet spinning, electron spinning, cast film solution, and the like. The dope solution is prepared by adding the solvent to the protein component and adjusting the viscosity to allow spinning. The solvent includes the polar solvent and an inorganic salt. Alternatively, the solvent may contain the alcohol and / or water in addition to the polar solvent and the inorganic salt. For example, the solution viscosity is 100 to 10,000 cP (centipoise). The solution viscosity is measured using, for example, a trade name “EMS viscometer” manufactured by Kyoto Electronics Industry Co., Ltd. In addition, the solution of the polypeptide of the present invention may contain unavoidable components such as impurities contained in a polypeptide derived from silk fibroin or spider silk protein.

4). Wet spinning-drawing (1) Wet spinning Wet spinning is adopted. Thereby, the solvent in which the polymer is dissolved is removed (also referred to as solvent removal or coagulation), and an undrawn yarn is obtained. The coagulation liquid used for wet spinning may be any solution as long as it can be desolvated. It is preferable to use a lower alcohol having 1 to 5 carbon atoms such as methanol, ethanol, 2-propanol or acetone as the coagulation liquid for removing the solvent and forming fibers. You may add water suitably. The temperature of the coagulation liquid is preferably 3 to 30 ° C. If it is the said range, spinning will be stabilized. An undrawn yarn is obtained by extruding the spinning solution into a coagulating solution. In the case of a syringe pump having a nozzle having a diameter of 0.1 to 0.6 mm, the extrusion speed is preferably 0.2 to 2.4 ml / h per hole. Within this range, spinning is stable. A more preferable extrusion rate is 0.6 to 2.2 ml / h per hole. The length of the coagulation bath is preferably 200 to 500 mm, the undrawn yarn take-up speed is 1 to 3 m / min, and the residence time is preferably 0.01 to 0.15 min. If it is this range, solvent removal can be performed efficiently. Stretching (pre-stretching) may be performed in the coagulating liquid. However, in consideration of evaporation of the lower alcohol, it is preferable to keep the coagulating liquid at a low temperature and take it up in an unstretched yarn state.

(2) Stretching Stretching may be single-stage stretching or multi-stage stretching of two or more stages. Multi-stage stretching has the advantage of increasing stress.

  1 and 2 show examples of multistage stretching, and FIG. 1 shows a continuous process of spinning and stretching. The spinning drawing device 10 includes an extrusion device 1, an undrawn yarn manufacturing device 2, a wet heat drawing device 3, and a dry heat drawing device 4. The spinning solution 6 is stored in a storage tank 7 and is pushed out from the base 9 using a gear pump 8. In the lab scale, the spinning solution may be filled into a cylinder and extruded from a nozzle using a syringe pump. The extruded spinning solution has an air gap 19 or is directly supplied into the coagulating liquid 11 in the coagulating liquid tank 20 to remove the solvent. Subsequently, it supplies in the hot water 12 in the extending bathtub 21, and extends | stretches the 1st step | paragraph. The draw ratio is determined by the speed ratio between the supply nip roller 13 and the take-up nip roller 14. Next, it is supplied to the dry heat drawing device 17, and the second stage drawing is performed in the yarn path 22 to obtain a wound yarn body 5. The draw ratio is determined by the speed ratio between the supply nip roller 15 and the take-up nip roller 16. Reference numerals 18a to 18f denote thread guides.

  2A-B are examples of two-stage stretching. 2A shows the spinning device 30 and the first stage stretching device 40, and FIG. 2B shows the second stage stretching device 50. The yarn may be wound up in each device or may be stored in the container without being wound up. In the spinning device 30, the spinning solution 32 is placed in the microsyringe 31, moved in the direction of arrow P using a syringe pump, the spinning solution 32 is pushed out from the nozzle 33, and the coagulating solution 35 in the coagulating solution tank 34 is discharged. The undrawn yarn 36 is supplied. Subsequently, in the first-stage drawing device 40, the undrawn yarn 36 is supplied into the hot water 38 in the drawing bath 37, and the first-stage drawing is performed to obtain a wound body 39 of the first-stage drawn yarn. The draw ratio is determined by the speed ratio between the supply nip roller 41 and the take-up nip roller 42. Next, the first-stage drawn yarn is pulled out from the wound yarn body 39, supplied to the dry heat drawing apparatus 43, and drawn in the second stage in the yarn path 47. The draw ratio is determined by the speed ratio between the supply nip roller 45 and the take-up nip roller 46. Next, the drawn yarn is wound around the wound body 44.

  3 to 4 are examples of single-stage stretching, and FIG. 3 shows a continuous process. The spinning / drawing device 60 includes an extrusion device 61, an undrawn yarn manufacturing device 62, and a dry heat drawing device 63. The spinning solution 66 is stored in a storage tank 67 and pushed out from a base 69 by a gear pump 68. In the lab scale, the spinning solution may be filled into a cylinder and extruded from a nozzle using a syringe pump. The extruded spinning solution has an air gap 73 or is directly supplied into the coagulating liquid 71 in the coagulating liquid tank 72 to remove the solvent. Next, it is supplied to the dry heat drawing device 77 and drawn in the yarn path 78 to obtain a wound body 64. The draw ratio is determined by the speed ratio between the supply nip roller 75 and the take-up nip roller 76. 74a to 74f are thread guides.

  4A and 4B are explanatory views of an example in which spinning and stretching are separated. 4A shows a spinning device 80, and FIG. 4B shows a drawing device 90. FIG. The yarn may be wound up in each device or may be stored in the container without being wound up. In the spinning device 80, the spinning solution 82 is placed in the microsyringe 81, moved in the direction of arrow P using a syringe pump, the spinning solution 82 is pushed out from the nozzle 83, and the coagulating solution 85 in the coagulating solution tank 84 is discharged. The unwound yarn wound body 86 is supplied. Next, in the drawing device 90, the undrawn yarn is pulled out from the wound body 86, supplied to the dry heat drawing device 89, and drawn in the yarn path 91. The draw ratio is determined by the speed ratio between the supply nip roller 87 and the take-up nip roller 88. Next, the drawn yarn is wound around the wound body 92. Thereby, a drawn yarn is obtained.

  In the method of the present invention, hot water bath stretching can be performed in advance before dry heat heating stretching. The molecular orientation can be further advanced by hot water bath stretching. Hot water bath drawing is also useful for mixed (hybrid) fibers of silk fibroin and spider silk protein. The hot bath stretching conditions are preferably 30 to 90 ° C. and a stretching ratio of 1.05 to 6 times.

  The protein fiber obtained by wet spinning-drawing preferably has a diameter in the range of 5 to 100 μm. If it is the said range, a fiber can be obtained stably. A more preferable fiber diameter is in the range of 8 to 50 μm, and further preferably in the range of 20 to 40 μm. The protein fiber obtained by wet spinning-drawing is not limited to a circular cross section, and includes various shapes, and thus refers to an average diameter when the cross section is assumed to be circular.

5. Cast film The protein solution of the present invention can be formed into a cast film as a dope solution. For example, the protein solution is obtained by casting the dope solution to a predetermined thickness on a flat plate resistant to the solvent in the dope solution, such as a glass plate, and removing the solvent from the cast film. To cast the dope solution to a specified thickness, cast it to a thickness of several microns or more using a jig such as a doctor coat or knife coater, and then remove the solvent by drying under reduced pressure or immersion in a solvent removal tank. By getting.

6). Crosslinking The protein fiber or film of the present invention may chemically crosslink between polypeptide molecules. Examples of functional groups that can be used for cross-linking of polypeptides include amino groups, carboxyl groups, thiol groups, and hydroxy groups, but are not limited thereto. The amino group of the lysine side chain contained in the polypeptide can be cross-linked with an amide bond by dehydration condensation with the carboxyl group of the glutamic acid or aspartic acid side chain. Crosslinking may be carried out by dehydration condensation reaction under vacuum heating, or by dehydration condensation agent such as carbodiimide. Moreover, you may use crosslinking agents, such as glutaraldehyde. Moreover, it can also bridge | crosslink with enzymes, such as transglutaminase. As an example, a cross-linking reaction may be performed with a cross-linking agent such as carbodiimide, glutaraldehyde, or a polyfunctional epoxy resin (for example, trade name “Denacol” manufactured by Nagaze ChemteX). The carbodiimide is represented by the general formula R 1 N═C═NR 2 (where R 1 and R 2 represent an organic group containing an alkyl group having 1 to 6 carbon atoms or a cycloalkyl group), and the specific compound is 1 -Ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), N, N'-dicyclohexylcarbodiimide (DCC), 1-cyclohexyl-3- (2-morpholinoethyl) carbodiimide, diisopropylcarbodiimide (DIC), etc. There is. Among these, EDC and DIC are preferable because they have a high amide bond forming ability of peptide chains and easily undergo a crosslinking reaction. The cross-linking treatment may be performed by adding a cross-linking agent to the dope solution, or by applying a cross-linking agent to the drawn yarn and performing cross-linking by vacuum heat drying. A 100% product of the crosslinking agent may be imparted to the fiber, or it may be diluted with a lower alcohol having 1 to 5 carbon atoms or a buffer solution and imparted to the fiber at a concentration of 0.005 to 10% by mass. The treatment conditions are preferably a temperature of 20 to 45 ° C. and a time of 3 to 42 hours. Strength, toughness, chemical resistance, and the like can be increased by a crosslinking treatment with a crosslinking agent.

  Hereinafter, the present invention will be described more specifically with reference to examples. In addition, this invention is not limited to the following Example.

(Example 1)
(1) Preparation of silk fibroin raw material (a) The cocoon was cut into about 2 mm × 10 mm and boiled for about 30 minutes with boiling 0.5% by weight Marcel soap water (use Marcel soap finely ground with grater) .
(B) Then, it boiled for 30 minutes with boiling hot water.
(C) Procedures 1 and 2 were repeated twice (total 3 times).
(D) Finally boiled in boiling water for 30 minutes. By this operation, sericin and other additives covering the silk fibroin were completely removed.
(E) Wet silk fibroin was dried overnight at 37 ° C.
(F) The dried silk was weighed, and LiBr aqueous solution (9 mol / L) was added so as to be 10 w / v% (mass%), and dissolved in a 40 ° C. environment for 2 hours.
(G) The aqueous solution was put into a cellulose dialysis membrane (Seamless Cellulose Tubing, 36/32 manufactured by VISKASESELES COAP) and dialyzed for 3 to 4 days using distilled water.
(H) The recovered solution after dialysis was centrifuged at 20 ° C., 15,000 rpm for 1 hour to remove undissolved parts and dust.
(I) Furthermore, it diluted with MilliQ so that a density | concentration might be 2 mass% or less.
(J) After dilution, the fine dust was completely removed by passing through a 150 μm filter manufactured by ADVANTEC.
(K) The silk fibroin aqueous solution was frozen in an environment of −80 ° C. and lyophilized overnight. After confirming that water was sufficiently removed, it was stored as silk fibroin powder. In this way, silk fibroin freeze-dried powder was obtained.

2. Solvent (polar solvent and solubility promoter)
(1) Polar Solvent The polar solvent was investigated mainly for polar solvents used as polymerization solvents for acrylic fiber polymerization, spinning solution, and polyimide.
DMA: N, N-dimethylacetamide DMF: N, N-dimethylformamide DMI: 1,3-dimethyl-2-imidazolidinone NMP: N-methyl-2-pyrrolidone HFIP: hexafluoroisopropanol DMSO: dimethyl sulfoxide formate butyric carbonate Propylene carbonate γ-butyrolactone hexamethylphosphoramide
(2) Dissolution promoter (inorganic salt)
The following inorganic salts were examined as dissolution promoters.
Alkali metal halides: LiCl, LiBr
Alkaline earth metal halide: CaCl 2
Alkaline earth metal nitrate: Ca (NO 3 ) 2
Sodium thiocyanate: NaSCN

<Solubility test>
As shown in Table 1, a solubility test was conducted using a polar solvent and a system in which an inorganic salt was added thereto. The temperature was 100 ° C. The silk fibroin concentration was 4% by mass. The solubility evaluation shown in Table 1 and below was based on the following criteria. In Table 1, mass% of the inorganic salt is a ratio of the mass of the inorganic salt to the total mass of the polar solvent and the inorganic salt.
[Solubility Evaluation Criteria]
A Dissolve.
B Mostly dissolves but some insolubles remain.
C Does not dissolve.

  As is apparent from Table 1, dimethyl sulfoxide (DMSO), N, N-dimethylformamide (DMF), N, N-dimethylacetamide (DMA) and N-methyl-2-pyrrolidone (NMP) and a solvent containing an inorganic salt If so, it was confirmed that the solubility was selectively high and high temperature dissolution was possible.

  Next, the spinnability was examined for those having a solubility evaluation standard of A in Table 1. The spinnability employs wet spinning, and in the spinning apparatus shown in FIG. 4A, the spinning solution is filled into a cylinder, extruded from a 0.3 mm diameter nozzle using a syringe pump at a rate of 2.0 ml / h, 100 mass It was judged whether or not an undrawn yarn could be prepared by extracting the solvent in a% methanol coagulation solution. The length of the solvent removal tank (coagulation liquid tank) was 250 mm, and the winding speed was 2.1 m / min. As a result, any of the solubility evaluation criteria of Table 1 with A was spinnable.

(Example 2)
A fiber was prepared by wet spinning using a spinning solution (dope solution) and drawing.
(1) Preparation of spinning solution (dope solution) The protein component concentration (dope concentration) was 15% by mass, and the solvent was DMSO + 10% by mass LiCl.
(2) Wet spinning The spinning apparatus shown in FIG. 3 was used. Each condition in wet spinning is as follows.
Extrusion nozzle diameter: 0.3 mm
Extrusion speed: 3.0ml / h
Hot water temperature of the coagulation bath: 10 ° C
(3) Stretching Stretch ratio in warm water at 50 ° C. (single-stage stretching): 3.0 times Winding speed: 6.6 m / min (66 rpm).
(4) Physical properties of the obtained drawn yarn The physical properties of the obtained fiber were measured as follows. As a result, the average diameter of single fibers: 37.0 μm, maximum point stress: 135.1 MPa, initial elastic modulus: 5.8 GPa, displacement at break (elongation): 71.4%, toughness: 82.4 MJ / m 3 Met. The stress-displacement (strain) curve of the obtained single fiber is shown in FIG.
(A) The fiber diameter was determined using an optical microscope.
(B) Tensile test Temperature: Fiber strength and initial elastic modulus (at a maximum slope of 20 points) using a tensile tester (Shimadzu small tabletop tester EZ-S) at an ambient temperature of 25 ° C. and a relative humidity of 60%. Measurement was performed at intervals of 50 msec, and the maximum inclination when the inclination was calculated at intervals of 20 points was defined as the initial elastic modulus.) The elongation was measured and the toughness was calculated. The sample was affixed to a cardboard made of cardboard, and the distance between grips was 20 mm, and the pulling speed was 10 mm / min. The load cell capacity was 1N, and the gripping jig was a clip type. The measured value was an average value of the number of samples n = 5. The toughness calculation formula was as follows.
[E / (r 2 × π × L) × 1000] (unit: MJ / m 3 )
However,
E Breaking energy (Unit: J)
r Radius of fiber (unit: mm)
π Circumference ratio L Distance between grips during tensile test measurement: 20 mm

(Examples 3 to 7)
This example is an example of a hybrid fiber in which silk fibroin and a polypeptide derived from spider silk protein are mixed.
1. Preparation of polypeptide derived from spider silk protein <Gene synthesis>
(1) Synthesis of ADF3Kai gene A partial amino acid sequence of ADF3 (NCBI accession number: AAC47010, GI: 1263287), one of the two main worm-coiled silkworm proteins, is obtained from the NCBI web database. A gene encoding an amino acid sequence (SEQ ID NO: 2) in which an amino acid sequence (SEQ ID NO: 4) comprising a start codon, a His10 tag and a recognition site for HRV3C protease (Human rhinovirus 3C protease) is added to the N-terminal of the same sequence is sent to GenScript. Commissioned synthesis. As a result, a pUC57 vector (with an Nde I site immediately upstream of the 5 ′ end and an Xba I site immediately downstream of the 5 ′ end) into which the ADF3Kai gene having the base sequence represented by SEQ ID NO: 5 had been introduced was obtained. Thereafter, the gene was treated with restriction enzymes with Nde I and EcoR I and recombined into a pET22b (+) expression vector.

(2) Synthesis of ADF3Kai-Large Gene A PCR reaction was carried out using ADF3Kai as a template using T7 promoter primer (SEQ ID NO: 8) and Rep Xba I primer (SEQ ID NO: 9), and the 5 ′ half of the ADF3Kai gene sequence The sequence (hereinafter referred to as “sequence A”) was amplified, and the fragment was subjected to restriction enzyme treatment with Nde I and Xba I in advance using a Mighty Cloning Kit (manufactured by Takara Bio Inc.). Recombined. Similarly, a PCR reaction was performed using ADF3Kai as a template and an Xba I Rep primer (SEQ ID NO: 10) and a T7 terminator primer (SEQ ID NO: 11), and the sequence of the 3 ′ half of the gene sequence of ADF3Kai (hereinafter referred to as sequence B and The fragment was recombined into a pUC118 vector previously treated with Xba I and EcoR I using a Mighty Cloning Kit (Takara Bio Inc.). The pUC118 vector into which the sequence A was introduced was treated with Nde I and Xba I, the pUC118 vector into which the sequence B was introduced was treated with restriction enzymes with Xba I and EcoR I, respectively, and the target DNA fragments of the sequences A and B were obtained by cutting out the gel. Was purified. The DNA fragments A and B and pET22b (+) previously treated with Nde I and EcoR I were subjected to a ligation reaction and transformed into E. coli DH5α. After confirming the insertion of the target DNA fragment by colony PCR using the T7 promoter primer and T7 terminator primer, a plasmid was extracted from the colony from which the band of the target size (3.6 kbp) was obtained, and the 3130xl Genetic Analyzer (Applied) The entire base sequence was confirmed by a sequence reaction using Biosystems). As a result, the construction of the ADF3Kai-Large gene shown in SEQ ID NO: 6 was confirmed. The amino acid sequence of ADF3Kai-Large is as shown in SEQ ID NO: 3.

(3) Synthesis of ADF3Kai-Large-NRSH1 Gene Site Using PrimeStar Mutagenesis Basal Kit (manufactured by Takara Bio Inc.) using the pET22b (+) vector introduced with the ADF3Kai-Large gene obtained above as a template. By specific mutagenesis, the codon GGC corresponding to the 1155th amino acid residue glycine (Gly) in the amino acid sequence of ADF3Kai-Large (SEQ ID NO: 3) was mutated to the stop codon TAA, and ADF3Kai-Large shown in SEQ ID NO: 7 was obtained. -The gene for NRSH1 was constructed on pET22b (+). The accuracy of the introduction of the mutation was confirmed by a sequencing reaction using 3130xl Genetic Analyzer (Applied Biosystems). The amino acid sequence of ADF3Kai-Large-NRSH1 is as shown in SEQ ID NO: 1.

The pET22b (+) expression vector containing the gene sequence of ADF3Kai-Large-NRSH1 obtained above was transformed into Escherichia coli Rosetta (DE3). After culturing the obtained single colony in 2 mL of LB medium containing ampicillin for 15 hours, 1.4 ml of the same culture solution was added to 140 mL of LB medium containing ampicillin and cultured at 37 ° C. and 200 rpm. The culture was continued until the OD 600 was 3.5. Then, OD 600 of the culture broth of 3.5, added with 50% glucose 140mL in 2 × YT medium 7L containing ampicillin, and further cultured until an OD 600 of 4.0. Thereafter, isopropyl-β-thiogalactopyranoside (IPTG) was added to the obtained culture solution having an OD 600 of 4.0 so that the final concentration was 0.5 mM to induce protein expression. When 2 hours had elapsed after the addition of IPTG, the culture solution was centrifuged to recover the cells. When a protein solution prepared from a culture solution before and after IPTG addition was run on a polyacrylamide gel, a band of a target size (about 101.1 kDa) was observed depending on the addition of IPTG, and the target protein was It was confirmed that it was expressed. Escherichia coli expressing the ADF3Kai-Large-NRSH1 protein was stored in a freezer (−20 ° C.).

<Protein extraction and purification>
(I) About 4.5 g of Escherichia coli cells expressing the ADF3Kai-Large-NRSH1 protein and 30 ml of buffer AI (20 mM Tris-HCl, pH 7.4) are added to the centrifuge tube (50 ml), and a mixer is added. (GE “SI-0286”, level 10) is used to disperse the cells and then centrifuged (10,000 rpm, 10 minutes, room temperature) with a centrifuge (“MX-305” manufactured by Tommy Seiko). The supernatant was discarded.
(II) 30 ml of buffer AI and 0.3 ml of 0.1M PMSF (dissolved in isopropanol) are added to the precipitate (bacteria) obtained by centrifugation, and the above-mentioned mixer (level 10) manufactured by GE For 3 minutes. Thereafter, the microbial cells were crushed using an ultrasonic crusher (“VCX500” manufactured by SONIC & MATERIALS INC), and centrifuged (10,000 rpm, 10 minutes, room temperature).
(III) 30 ml of buffer solution AI is added to the precipitate obtained by centrifugation and dispersed for 3 minutes with a mixer (“T18 Basic Ultra Turrax”, level 2) manufactured by IKA, and then centrifuged by Tommy Seiko. The mixture was centrifuged (10,000 rpm, 10 minutes, room temperature), and the supernatant was removed.
(IV) 7.5 M urea buffer I (7.5 M urea, 10 mM sodium dihydrogen phosphate, 20 mM NaCl, 1 mM Tris-HCl, pH 7.0) was added to the centrifuge tube where the supernatant was discarded, and the above SMT company The precipitate was well dispersed with an ultrasonic crusher (level 7). Then, it was dissolved for 120 minutes with the shaker (200 rpm, 60 ° C.) manufactured by Taitec Corporation. The dissolved protein solution is centrifuged (11,000 × g, 10 minutes, room temperature) with the above-mentioned Tommy Seiko centrifuge, and the supernatant is used with a dialysis tube (Sanko Junyaku Co., Ltd. cellulose tube 36/32). And dialyzed against water. The white aggregated protein obtained after dialysis was recovered by centrifugation, the water was removed with a freeze dryer, and the lyophilized powder was recovered. The degree of purification of the target protein ADF3Kai-Large-NRSH1 (about 101.1 kDa) in the obtained lyophilized powder was obtained by imaging the result of polyacrylamide gel electrophoresis (CBB staining) of the powder using Totallab (nonlinear dynamics ltd.). This was confirmed by analysis. As a result, the degree of purification of ADF3Kai-Large-NRSH1 was about 85%.

2. Preparation of spinning solution (dope solution) A dope solution was prepared in the same manner as in Example 2. Specific conditions are shown in Table 2. Silk fibroin and spider silk protein were mixed when preparing the dope solution. The same silk fibroin as in Example 1 was used.

3. Stretching conditions and results Stretching was performed in a hot water bath as the first stretching, and second stretching was performed in a hot water bath (Examples 3 to 5 and 7) and dry heat (Example 6). The hot water bath stretching of the first stretching was performed continuously after the coagulation step. Table 2 shows the mass mixing ratio of silk fibroin and spider silk protein, the conditions of the stretching process, and Table 3 shows the results of the physical properties measured as described above.

  From the results in Tables 2 to 3, it can be seen that the physical properties of the hybrid fiber in which silk fibroin and spider silk protein are mixed are high.

  The protein solution of the present invention and the protein fiber using the protein solution can be suitably used for resin or metal reinforcing fibers, composite materials, injection molding and the like. The application can be applied to transportation equipment members such as automobiles and reinforcing fibers for tires. Furthermore, it can be applied to surgical threads, masks, filters, wound dressings, regenerative medical sheets, biosheets and the like. Applicable to woven fabrics, knitted fabrics, braided fabrics, nonwoven fabrics, etc.

1,31,61,81 Extruding device 2,30,62,80 Undrawn yarn production device 3,40 Wet heat drawing device (first-stage drawing device)
4, 50, 63, 90 Dry heat stretching device (second stage stretching device)
5, 39, 44, 64, 86, 92 Winding body 6, 32, 66, 82 Spinning liquid 7 Storage tank 8 Gear pump 9, 69, 83 Base 10, 60 Spinning and drawing device 11, 35, 71, 85 Coagulating liquid 36 Not yet Drawing yarns 12, 38 Hot water 13, 15, 41, 45 Supply nip rollers 14, 16, 42, 46 Take-off nip rollers 17, 43, 77, 89 Dry heat drawing devices 18a-18f Thread guides 19, 73 Air gaps 20, 34, 72 , 84 Coagulating liquid tank 21, 37 Stretch bath 22, 47, 78, 91 Thread path

SEQ ID NO: 1-4 Amino acid sequence SEQ ID NO: 5-7 Base sequence SEQ ID NO: 8-11 Primer sequence

The present invention relates to a process for producing a free Muta protein fibers silk fibroin.

Since the present invention is to solve the conventional problems, high solubility in a medium, but may be hot melted high boiling point, safety is high, including Muta protein fibers solvent costs themselves cheap silk fibroin A manufacturing method is provided.

The process for producing a protein fibers of the invention, silk fibroin di methylsulfonyl a protein component comprising a sulfoxide, N, N- dimethylformamide, N, at least one polar solvent selected from N- dimethylacetamide and N- methyl-2-pyrrolidone A protein fiber obtained by dissolving in a solution containing inorganic salt and a dope solution, and spinning the dope solution. The dope solution is extruded from a die into a coagulation bath and the polar solvent is desorbed. The fibers are formed into undrawn yarns, and the undrawn yarns are drawn in the first stage in a hot water bath to obtain drawn fibers.

(Example 1 , Reference example )
(1) Preparation of silk fibroin raw material (a) The cocoon was cut into about 2 mm × 10 mm and boiled for about 30 minutes with boiling 0.5% by weight Marcel soap water (use Marcel soap finely ground with grater) .
(B) Then, it boiled for 30 minutes with boiling hot water.
(C) Procedures 1 and 2 were repeated twice (total 3 times).
(D) Finally boiled in boiling water for 30 minutes. By this operation, sericin and other additives covering the silk fibroin were completely removed.
(E) Wet silk fibroin was dried overnight at 37 ° C.
(F) The weight of silk after drying was measured, LiBr aqueous solution (9 mol / L) was added so that it might become 10 w / v%, and it was made to melt | dissolve in a 40 degreeC environment for 2 hours.
(G) The aqueous solution was put into a cellulose dialysis membrane (Seamless Cellulose Tubing, 36/32 manufactured by VISKASESELES COAP) and dialyzed for 3 to 4 days using distilled water.
(H) The recovered solution after dialysis was centrifuged at 20 ° C., 15,000 rpm for 1 hour to remove undissolved parts and dust.
(I) Furthermore, it diluted with MilliQ so that a density | concentration might be 2 mass% or less.
(J) After dilution, the fine dust was completely removed by passing through a 150 μm filter manufactured by ADVANTEC.
(K) The silk fibroin aqueous solution was frozen in an environment of −80 ° C. and lyophilized overnight. After confirming that water was sufficiently removed, it was stored as silk fibroin powder. In this way, silk fibroin freeze-dried powder was obtained.

The method for producing a protein fiber of the present invention comprises a protein component containing silk fibroin, at least one polar solvent selected from dimethyl sulfoxide, N, N-dimethylformamide, N, N-dimethylacetamide and N-methyl-2-pyrrolidone, and A method for producing a protein fiber obtained by dissolving in a solution containing an inorganic salt to obtain a dope solution, and spinning the dope solution. The dope solution is extruded from a base into a coagulation solution tank, and the temperature of the coagulation solution is 3 -30 ° C, residence time in the coagulation tank is 0.01-0.15 min, the polar solvent is desorbed and fibers are formed into undrawn yarn, and the undrawn yarn is hot water having a hot water temperature of 30-90 ° C. The first stage is drawn in a bath to obtain drawn fibers.

Claims (11)

  1. A protein solution in which a protein component containing silk fibroin is dissolved in a solvent,
    The protein solution contains at least one polar solvent selected from dimethyl sulfoxide, N, N-dimethylformamide, N, N-dimethylacetamide and N-methyl-2-pyrrolidone and an inorganic salt.
  2.   The protein component containing the said silk fibroin is 100: 0-10: 90 polypeptide derived from a silk fibroin: spider silk protein by mass ratio when the said protein component is 100 mass%. Protein solution.
  3.   The protein solution according to claim 1 or 2, wherein a ratio of the protein component is in a range of 3 to 45 mass% when the protein solution is 100 mass%.
  4.   The protein solution according to any one of claims 1 to 3, wherein the proportion of the inorganic salt is in the range of 0.1 to 20 mass% when the solvent is 100 mass%.
  5.   The protein solution according to any one of claims 1 to 4, wherein when the solvent is 100% by mass, the ratio of the polar solvent and the inorganic salt is 20% by mass or more and 100% by mass or less, and the remainder contains alcohol. .
  6.   The protein solution according to any one of claims 1 to 5, wherein when the solvent is 100 mass%, the ratio of the polar solvent and the inorganic salt is 10 mass% or more and 100 mass% or less, and the balance contains water. .
  7.   The protein solution according to any one of claims 1 to 6, wherein the inorganic salt is at least one selected from an alkali metal halide, an alkaline earth metal halide, an alkaline earth metal nitrate, and a thiocyanate.
  8.   The protein solution according to any one of claims 1 to 7, wherein the solution is a dope solution for spinning fibers or a dope solution for casting a film.
  9. A method for producing a protein fiber containing silk fibroin using the protein solution according to any one of claims 1 to 8 as a dope solution,
    A method for producing a protein fiber, characterized in that the dope solution is extruded from a die into a coagulation solution in a solvent removal tank to remove the solvent from the dope solution and form fibers to form undrawn yarn to obtain protein fibers.
  10.   Furthermore, the manufacturing method of the protein fiber of Claim 9 including the process of extending | stretching the said undrawn yarn.
  11. The method for producing a protein fiber according to claim 10, wherein the stretching is multistage stretching.
JP2013541771A 2011-11-02 2012-10-29 Method for producing protein fiber Active JP5584932B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2011241487 2011-11-02
JP2011241487 2011-11-02
JP2013541771A JP5584932B2 (en) 2011-11-02 2012-10-29 Method for producing protein fiber
PCT/JP2012/077922 WO2013065651A1 (en) 2011-11-02 2012-10-29 Protein solution and production method for protein fiber using same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013541771A JP5584932B2 (en) 2011-11-02 2012-10-29 Method for producing protein fiber

Publications (2)

Publication Number Publication Date
JP5584932B2 JP5584932B2 (en) 2014-09-10
JPWO2013065651A1 true JPWO2013065651A1 (en) 2015-04-02

Family

ID=48191998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541771A Active JP5584932B2 (en) 2011-11-02 2012-10-29 Method for producing protein fiber

Country Status (2)

Country Link
JP (1) JP5584932B2 (en)
WO (1) WO2013065651A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012165476A1 (en) 2011-06-01 2012-12-06 スパイバー株式会社 Artificial polypeptide fiber and method for producing same
US9689089B2 (en) 2012-06-28 2017-06-27 Spiber Inc. Solution-dyed protein fiber and method for producing same
EP2940066A4 (en) * 2012-12-26 2016-07-06 Spiber Inc Spider silk protein film, and method for producing same
CN103861149B (en) * 2014-03-14 2015-06-17 苏州大学 Durably-transparent silk fibroin film and preparation method thereof
WO2016163336A1 (en) * 2015-04-09 2016-10-13 Spiber株式会社 Polar solvent solution and production method thereof
WO2016163337A1 (en) * 2015-04-09 2016-10-13 Spiber株式会社 Polar solvent solution and production method thereof
JPWO2017094722A1 (en) * 2015-12-01 2018-10-11 Spiber株式会社 Method for producing a protein solution
JPWO2018066558A1 (en) 2016-10-03 2019-09-05 Spiber株式会社 Purification method of recombinant protein
WO2018116979A1 (en) 2016-12-20 2018-06-28 Spiber株式会社 Fiber-reinforced resin material and laminate
CN110099917A (en) * 2016-12-27 2019-08-06 丝芭博株式会社 The recovery method of protein
JP6337252B1 (en) * 2017-03-10 2018-06-06 Spiber株式会社 High shrinkage artificial fibroin fiber, method for producing the same, and method for shrinking artificial fibroin fiber
WO2018164190A1 (en) * 2017-03-10 2018-09-13 Spiber株式会社 Synthetic fibroin fiber
CN110546264A (en) * 2017-05-10 2019-12-06 丝芭博株式会社 Method for producing polypeptide solution and polypeptide fiber, and artificial polypeptide
WO2018235958A1 (en) * 2017-06-23 2018-12-27 Spiber株式会社 Method for purifying protein, method for producing protein solution, and method for producing protein moulded body
WO2019066037A1 (en) * 2017-09-29 2019-04-04 Spiber株式会社 Dope liquid and product using same, and structural protein fiber and method for producing same
WO2019151432A1 (en) * 2018-01-31 2019-08-08 Spiber株式会社 Method for preparing oil adhesion protein crimped fiber
WO2019151424A1 (en) * 2018-01-31 2019-08-08 Spiber株式会社 Fibroin composition, fibroin solution, and method for manufacturing fibroin fiber
WO2019194231A1 (en) * 2018-04-03 2019-10-10 Spiber株式会社 Protein composition and method for producing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0673098A (en) * 1992-08-27 1994-03-15 Kiyoichi Matsumoto Method for coagulation and coagulant
JP3460128B2 (en) * 1994-01-14 2003-10-27 大東ニット株式会社 The process of silk Fuiburoin fiber
ES2525095T3 (en) * 2004-07-22 2014-12-17 Amsilk Gmbh Recombinant spider silk proteins
JP5192391B2 (en) * 2005-12-30 2013-05-08 スパイバー・テクノロジーズ・アーベー Spider silk protein and spider silk protein production method
JP2009138322A (en) * 2007-11-14 2009-06-25 Toray Ind Inc Method for producing monofilament

Also Published As

Publication number Publication date
WO2013065651A1 (en) 2013-05-10
JP5584932B2 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
Huang et al. Generation of synthetic elastin-mimetic small diameter fibers and fiber networks
Guthold et al. A comparison of the mechanical and structural properties of fibrin fibers with other protein fibers
Zhou et al. Silk fibers extruded artificially from aqueous solutions of regenerated Bombyx mori silk fibroin are tougher than their natural counterparts
Rabotyagova et al. Self-assembly of genetically engineered spider silk block copolymers
US5514581A (en) Functional recombinantly prepared synthetic protein polymer
Buttafoco et al. Electrospinning of collagen and elastin for tissue engineering applications
Seidel et al. Artificial spinning of spider silk
EP0488687B1 (en) A process for spinning polypeptide fibers
Wang et al. Exploring natural silk protein sericin for regenerative medicine: an injectable, photoluminescent, cell-adhesive 3D hydrogel
Phillips et al. Regenerated silk fiber wet spinning from an ionic liquid solution
Wang et al. Effect of regeneration of liquid silk fibroin on its structure and characterization
Ha et al. Structural Study of Irregular Amino Acid Sequences in the Heavy Chain of Bombyx m ori Silk Fibroin
Shao et al. Structure and behavior of regenerated spider silk
Rammensee et al. Rheological characterization of hydrogels formed by recombinantly produced spider silk
CN101787582B (en) Preparation method of high-tensile high-model heterocycle aramid fiber
CN101018806B (en) Recombinant spider silk proteins
US20050010035A1 (en) Spider silk protein encoding nucleic acids, polypeptides, antibodies and methods of use thereof
US5733771A (en) cDNAs encoding minor ampullate spider silk proteins
Omenetto et al. New opportunities for an ancient material
CN1247837C (en) Method for producing fiber and film of silk and silk-like material
Chen et al. Conformation transition in silk protein films monitored by time-resolved Fourier transform infrared spectroscopy: effect of potassium ions on Nephila spidroin films
JP2005515309A (en) Polypeptide fibers and methods for their production
Wang et al. Mechanical properties of electrospun silk fibers
CA2465276C (en) Precursor feedstock for forming filaments
Yao et al. Artificial Spinning and Characterization of Silk Fiber from Bombyx m ori Silk Fibroin in Hexafluoroacetone Hydrate

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140610

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140703

R150 Certificate of patent or registration of utility model

Ref document number: 5584932

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140801

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250